Harun Zengin

Harun Zengin

Auto-generated profile, based on publicly available information

Harun Zengin

Department of Anesthesiology and Intensive Care, Ankara Bilkent City Hospital, Ankara, Türkiye

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2026 in The Anatolian Journal of Cardiology
Verified
Journal Article
Open access
PDF file
HZHarun Zengin
Harun Zengin
CACemalettin Akman
Cemalettin Akman
BABekir Boğaçhan Akkaya
Bekir Boğaçhan Akkaya
MYMehmet Yılmaz
Mehmet Yılmaz
ZDZeliha Aslı Demir
Zeliha Aslı Demir
HMHayri Levent Mavioğlu
Hayri Levent Mavioğlu
The Anatolian Journal of Cardiology - Peer-reviewed cardiology journal publishing original research, reviews, case reports. Impact Factor 1.5. The Anatolian Journal of Cardiology - Leading international cardiology journal with Impact Factor 1.5. Publishing original research, reviews, and case reports in cardiovascular medicine. Indexed in PubMed, Scopus, and Web of Science.

1 March 2012 in International Journal of Cardiology
Verified
Journal Article
Closed access
GNG. Nar
G. Nar
SYSerkan Yüksel
Serkan Yüksel
RNR. Nar
R. Nar
MMM. Meriç
M. Meriç
KSK. Soylu
K. Soylu
MŞmerve karaca şahin
merve karaca şahin

1 March 2012 in International Journal of Cardiology
Verified
Journal Article
Closed access
SYSerkan Yüksel
Serkan Yüksel
AEA. Erbay
A. Erbay
AYAhmet Yanik
Ahmet Yanik
MMM. Meriç
M. Meriç
KSK. Soylu
K. Soylu
MŞM. Şahin
M. Şahin

6 August 2024 in Eurasian Journal of Anesthesiology and Intensive Care
Verified
Journal Article
Open access
PDF file
HZHarun Zengin
Harun Zengin
EZEmine Nilgün Zengin
Emine Nilgün Zengin
NSNevriye Salman
Nevriye Salman
SŞSumru Şekerci
Sumru Şekerci
Malignant hyperthermia (MH) is a rare but one of the most serious complications of general anesthesia due to the hypermetabolic state of skeletal muscle. In this case, it was aimed to share the diagnosis and treatment of the patient who was diagnosed with MH intraoperatively during cardiac surgery. Consent was obtained from the 59-year-old patient who was scheduled for CABGx2 surgery on his beating heart. The patient had no comorbidities other than hypertension. He was a non-smoker and had no history of previous surgery. Hypermetabolic findings began in the 90th minute of the operation. Body temperature: 39°C; pCO2: 72 mmHg; pH: 7.15; potassium was 5.13 mEq/L and pulse was >120.min-1. MH was considered when the color change in soda lime started. After these findings, anesthesia was maintained with 100% oxygen and TIVA anesthesia. The patient, whose hemodynamic stabilization was achieved, was taken to the intensive care unit (ICU) in an intubated state at the end of the surgery. A single dose of 2.5 mg/kg iv dantrolene was administered in the ICU. After dantrolene, body temperature, hemodynamic and metabolic values returned to normal. The patient was extubated on the first postoperative day. The patient, who was followed up in the ICU for 2 days and in the ward for 5 days, was discharged without complications. Dantrolene is the specific antidote for MH. With early application, the risk of complications and mortality can be reduced. Therefore, attention should be paid to the clinical symptoms of MH, and as soon as MH is suspected, triggering agents should be removed immediately and dantrolene supply and treatment should be provided.